Nippon Life Global Investors Americas Inc. Has $4.03 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Nippon Life Global Investors Americas Inc. decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 15.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,840 shares of the medical research company’s stock after selling 9,460 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Edwards Lifesciences were worth $4,032,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Smithbridge Asset Management Inc. DE lifted its position in shares of Edwards Lifesciences by 3.0% during the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 15,710 shares of the medical research company’s stock valued at $1,222,000 after acquiring an additional 455 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its stake in Edwards Lifesciences by 45.5% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,702 shares of the medical research company’s stock valued at $832,000 after purchasing an additional 3,349 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Edwards Lifesciences by 2.0% during the third quarter. Maryland State Retirement & Pension System now owns 28,530 shares of the medical research company’s stock valued at $2,219,000 after purchasing an additional 556 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Edwards Lifesciences by 14.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 30,237 shares of the medical research company’s stock worth $2,352,000 after purchasing an additional 3,776 shares in the last quarter. Finally, Howland Capital Management LLC grew its stake in shares of Edwards Lifesciences by 3.9% in the 3rd quarter. Howland Capital Management LLC now owns 31,089 shares of the medical research company’s stock valued at $2,418,000 after buying an additional 1,153 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This represents a 22.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 57,824 shares of company stock worth $4,863,323 over the last three months. 1.29% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a report on Monday, January 12th. Evercore ISI reiterated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $90.00 to $97.00 in a research note on Friday, January 9th. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.45.

Edwards Lifesciences Stock Down 0.1%

EW stock opened at $84.39 on Friday. The stock has a market cap of $48.97 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $85.12 and its two-hundred day simple moving average is $80.57. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.